Lupin Limited has received approval from China’s National Medical Products Administration for its Abbreviated New Drug Application for Oseltamivir Phosphate Oral Suspension, marking the company’s first product approval and commercial entry into the Chinese pharmaceutical market. The approval has been secured in partnership with Yabao Pharmaceuticals, a leading player in China’s paediatric medicine segment. The product, Oseltamivir Phosphate for oral suspension 6 mg/mL, will be launched in China to improve access to influenza treatment and prevention, particularly for children.
The medicine is indicated for the treatment of influenza A and B in patients aged two weeks and older, as well as for the prevention of influenza A and B in individuals aged one year and above. The approval represents a major milestone in Lupin’s international expansion strategy and strengthens its presence in one of the world’s largest pharmaceutical markets.
Fabrice Egros, President – Corporate Development at Lupin, said the approval marks an important strategic step for the company’s entry into China. He noted that the collaboration with Yabao Pharmaceuticals reflects a shared commitment to expanding access to high-quality and affordable therapies, particularly within paediatric healthcare.
Wei Ren, President of Yabao Pharmaceuticals, said the approval demonstrates the strength of the partnership between the two companies and reinforces Yabao’s focus on quality-driven paediatric medicines. He added that the collaboration would support expansion of research and development efforts across paediatric and chronic disease therapies.
The launch is expected to strengthen Lupin’s global footprint while enhancing its portfolio of anti-infective and paediatric healthcare products. China’s growing demand for quality healthcare products and increasing focus on accessible treatment solutions continue to create opportunities for international pharmaceutical companies with strong manufacturing and regulatory capabilities.
Headquartered in Mumbai, Lupin operates across more than 100 global markets and specializes in branded and generic formulations, biotechnology products, complex generics and active pharmaceutical ingredients. The company maintains a strong presence across therapy areas including respiratory care, cardiovascular treatment, anti-diabetic therapies, gastrointestinal medicine, anti-infectives and women’s health.
Lupin operates 15 manufacturing facilities and seven research centers globally, supported by a workforce of more than 24,000 professionals. Through its subsidiaries including Lupin Diagnostics, Lupin Digital Health and Lupin Manufacturing Solutions, the company continues to focus on improving patient access, healthcare innovation and treatment outcomes worldwide.